+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: UCB

The publisher explores UCB’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot
  • Overview - UCB will experience impressive growth of its core portfolio of CNS and I&I products through 2021, but patent expiries will cause growth to slow over the long term.
  • Key themes - [1] UCB will see solid near-term revenue growth due to its strong immunology and neurology assets [2] UCB saw several positive readouts from the Phase III program for bimekizumab in late 2019 that bode well for future uptake of the product [3] Growth from pipeline products - bimekizumab, zilucoplan, and rozanolixizumab - and recently launched Nayzilam and Evenity will see UCB increase revenues over the forecast period [4] UCB has several sizable brands with upcoming loss of exclusivity: Vimpat in 2022, Cimzia in 2024, and Briviact in 2026.
Model updates (27 July 2020)
  • Bimekizumab forecast adjusted higher due to recent clinical trial results showing superiority to current standard-of-care
  • Zilucoplan forecast added after closing of Ra Pharma acquisition
  • Padsevonil forecast removed after UCB formally suspends program.
Model updates (20 May 2020)
  • Padsevonil forecast lowered due to disappointing results from the Phase IIb ARISE trial.
Model updates (20 February 2020)
  • Cimzia forecast adjusted higher
  • Evenity forecast adjusted in 5EU and RoW to reflect approval and launch in first half of 2020
  • Bimekizumab forecast adjusted higher due to strong results from three Phase III trials - BE VIVID, BE READY, and BE SURE.
Model updates (25 July 2019)
  • Cimzia forecast adjusted higher due to growth in new patient populations, such as women of childbearing age and people living with psoriasis
  • Vimpat forecast adjusted higher due to market share gains in all regions
  • Briviact forecast adjusted higher due to continued growth in all regions
  • Evenity launch in Europe delayed due to negative CHMP opinion and UCB appeal
  • Nayzilam forecast added
  • Padsevonil forecast added
  • Rozanolixizumab forecast added.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Recent Earnings Review
  • Earnings Overview
  • Pharma Insights Analysis
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll